. home.aspx

NEWS

home.aspx
   


Novavax Selects AGC Biologics to Manufacture Matrix-M™ Adjuvant for Novel COVID-19 Vaccine

June 03, 2020 / PR Newswire
SHARESHARESHARE

AGC Biologics, a global biopharmaceutical Contract Development and Manufacturing Organization (CDMO), has announced that it will partner with Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, on large-scale GMP production of a critical component of Novavax' coronavirus vaccine candidate, NVX-CoV2373. AGC Biologics will manufacture Matrix-M™, the  adjuvant component of the vaccine, in order to enhance the immune response and stimulate high levels of neutralizing antibodies. NVX-CoV2373 is a stable, prefusion protein made using Novavax' proprietary nanoparticle technology. AGC Biologics will optimize process development for scaled-up production of Matrix-M to significantly increase Novavax' capacity to deliver doses in 2020 and 2021. "We are quickly ramping up to successfully deliver this vital vaccine component to Novavax," says AGC Biologics' CEO Patricio Masser...